

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M. 9688 - CINVEN / ASTORG / LGC SCIENCE GROUP**

**SECTION 1.2**

**Description of the concentration**

The proposed concentration concerns the acquisition of joint indirect control of LGC Science Group Holdings Limited by affiliates of Seventh Cinven Fund (No. 1) Limited Partnership, a fund managed by Cinven Capital Management (VII) General Partner Limited, and Astorg VII Special Limited Partnership, a fund managed by Astorg Asset Management S.à r.l., within the meaning of Article 3(1)(b) of the the Merger Regulation.

- **Cinven** is a European private equity business engaged in the provision of investment management and investment advisory services to a number of investment funds. Cinven has offices in London, Frankfurt, Paris, Milan, Madrid, Guernsey, Luxembourg, Hong Kong and New York. Cinven's headquarters are in the United Kingdom.

- **Astorg** is an independent European private equity firm with over EUR 8 billion of assets under management and offices in London, Paris, Luxembourg, Frankfurt and Milan. Astorg's headquarters are in Luxembourg.

- **LGC** is headquartered in the United Kingdom ("UK"). LGC is a parent undertaking of a group of companies engaged in the provision of measurement tools, proficiency testing schemes, supply chain assurance standards, genomics reagents and instrumentation and research and measurement services. LGC operates two divisions: Standards and Genomics.